Dr Roy Baynes | SVP of Head Global Clinical Development, Chief Medical Officer
Merck Sharp and Dohme (MSD)

Dr Roy Baynes, SVP of Head Global Clinical Development, Chief Medical Officer, Merck Sharp and Dohme (MSD)

Roy Baynes is Senior Vice President and Head, Global Clinical Development and Chief Medical Officer at Merck Sharp & Dohme (MSD). He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.


EAC 2017 Day 1, Tuesday 31st October 2017 @ 09:35

Keynote: Anti PD-1 antibody therapy – a broad spectrum anticancer monotherapy and a backbone in combination therapy

  • A biologically informed screening phase 2 program has identified broad spectrum monotherapy activity
  • Pivotal trials have led to an expanding list of approved monotherapy indications
  • Biomarker research is aimed at identifying those who benefit maximally from monotherapy and those who might be studied with biologically informed combination therapies
  • An ever expanding number of highly active combinations are being advanced

EAC 2017 Day 2, Wednesday 1st November 2017 @ 09:05

Keynote Panel: Oncology strategies across pharma

  • High level pharma companies come together to discuss their strategies for tackling cancer
  • Each company will give a 5-minute presentation on their strategy, and a fire side discussion on oncology focused strategies will follow
  • Strategies will cover cytotherapy, checkpoint inhibitors, combination therapy, sequential therapy, approaches to solid tumours, treatments and diagnostics

back to speakers